Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells
Zhang C, Sun X, Ren Y, Lou Y, Zhou J, Liu M, Li D. Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells. Cancer Biology & Therapy 2012, 13: 1214-1220. PMID: 22892842, PMCID: PMC3469479, DOI: 10.4161/cbt.21412.Peer-Reviewed Original ResearchConceptsPancreatic cancer cellsCancer cellsPolo-like kinase 1Human pancreatic cancer cellsChemotherapeutic drug gemcitabinePLK1 inhibitorsCombination index analysisKinase 1Pancreatic cancerClinical investigationTherapeutic targetCancer treatmentExpression levelsDrug gemcitabineValuable targetCellsTreatmentInhibitorsProliferationCritical roleGekko-sulfated Glycopeptide Inhibits Tumor Angiogenesis by Targeting Basic Fibroblast Growth Factor*
Zhang S, Zhu C, Ba Y, Chen D, Zhou X, Cao R, Wang L, Ren Y, Wu X. Gekko-sulfated Glycopeptide Inhibits Tumor Angiogenesis by Targeting Basic Fibroblast Growth Factor*. Journal Of Biological Chemistry 2012, 287: 13206-13215. PMID: 22371501, PMCID: PMC3340002, DOI: 10.1074/jbc.m111.321521.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarcinoma, HepatocellularChick EmbryoChickensDrug DiscoveryDrugs, Chinese HerbalEarly Growth Response Protein 1Fibroblast Growth Factor 2GlucuronidaseHep G2 CellsHeparinHuman Umbilical Vein Endothelial CellsHumansLiver Neoplasms, ExperimentalMaleMiceMice, NudeNeovascularization, PathologicPolysaccharidesSurface Plasmon ResonanceXenograft Model Antitumor AssaysConceptsBasic fibroblast growth factorFibroblast growth factorTumor angiogenesisProduction of bFGFEndothelial cellsGrowth factorGekko swinhonis GuentherAbsence of bFGFInhibits tumor angiogenesisXenograft mouse modelLow-affinity receptorsEarly growth response 1Traditional Chinese medicineRelease of bFGFHeparan sulfateMouse modelTherapeutic targetHeparanase enzymatic activityTumor growthBFGF productionHeparin/heparan sulfateAffinity receptorInhibitory effectChinese medicineExtracellular matrixInhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration
Peng G, Ren Y, Sun X, Zhou J, Li D. Inhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration. Biochemical Pharmacology 2012, 83: 1374-1382. PMID: 22382068, DOI: 10.1016/j.bcp.2012.02.008.Peer-Reviewed Original ResearchConceptsEndothelial cellsCell migrationInhibition of farnesyltransferaseTherapeutic targetTumor cellsCancer treatmentEndothelial cell migrationUse of FTIsProtein 1Cancer therapyAngiogenesisPseudopodia formationInhibition of FTaseInhibitors of farnesyltransferaseInhibitionCellsLocalization of EB1Novel insightsPhysiological processesTherapy